CLINICAL TRIALS PROFILE FOR SAPHRIS
✉ Email this page to a colleague
All Clinical Trials for Saphris
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00281320 ↗ | Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2006-02-01 | This study evaluates the safety and tolerability of Asenapine in elderly patients with psychosis. |
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | GlaxoSmithKline | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT00833976 ↗ | Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia | Completed | Massachusetts General Hospital | Phase 4 | 2009-07-01 | This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated. |
| NCT00878462 ↗ | An Acceptability Study of Unflavored Asenapine Versus Raspberry Flavored Asenapine in Stable Patients With a Psychotic Disorder (P07010)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2005-06-29 | This trial was a randomized trial to determine a patient's acceptability of unflavored antipsychotic medication compared to raspberry flavored antipsychotic medication. Patients received 6 total doses of study drug (2 doses of each asenapine formulation) over 3 consecutive days: 2 different formulations each day, 1 in the morning and 1 in the evening. The formulations were: white unflavored, white raspberry flavored, and red raspberry flavored. Patients were given a questionnaire following each dose of study medication (one questionnaire twice per day for 3 days) to measure how acceptable each formulation was. |
| NCT01400113 ↗ | Treating Acutely Agitated Patients With Asenapine Sublingual Tablets | Completed | Schering-Plough | Phase 4 | 2012-04-01 | Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this purpose. Establishing the utility of asenapine for this common clinical problem will support its use as an additional treatment option in acutely agitated patients. |
| NCT01400113 ↗ | Treating Acutely Agitated Patients With Asenapine Sublingual Tablets | Completed | St. Joseph Hospital Health Center | Phase 4 | 2012-04-01 | Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this purpose. Establishing the utility of asenapine for this common clinical problem will support its use as an additional treatment option in acutely agitated patients. |
| NCT01400113 ↗ | Treating Acutely Agitated Patients With Asenapine Sublingual Tablets | Completed | Unity Health Toronto | Phase 4 | 2012-04-01 | Our proposal is to administer asenapine to patients who are clinically agitated and in need of immediate intervention. At present there are no controlled studies that we know of that explores the use of asenapine for this purpose. Establishing the utility of asenapine for this common clinical problem will support its use as an additional treatment option in acutely agitated patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Saphris
Condition Name
Clinical Trial Locations for Saphris
Trials by Country
Clinical Trial Progress for Saphris
Clinical Trial Phase
Clinical Trial Sponsors for Saphris
Sponsor Name
